Atwater Malick LLC Sells 24,178 Shares of Pfizer Inc. (NYSE:PFE)

Atwater Malick LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 13.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 149,761 shares of the biopharmaceutical company’s stock after selling 24,178 shares during the quarter. Pfizer accounts for 1.5% of Atwater Malick LLC’s investment portfolio, making the stock its 25th largest position. Atwater Malick LLC’s holdings in Pfizer were worth $4,156,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Wellington Management Group LLP lifted its position in shares of Pfizer by 4.9% during the 4th quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock valued at $6,886,849,000 after buying an additional 11,099,024 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Pfizer by 8.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 104,246,432 shares of the biopharmaceutical company’s stock valued at $2,985,783,000 after buying an additional 8,473,686 shares during the last quarter. Morgan Stanley lifted its position in shares of Pfizer by 0.4% during the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock valued at $2,817,055,000 after buying an additional 348,628 shares during the last quarter. Norges Bank purchased a new position in shares of Pfizer during the 4th quarter valued at $2,129,927,000. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Pfizer by 13.8% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 68,506,441 shares of the biopharmaceutical company’s stock valued at $1,972,300,000 after buying an additional 8,298,920 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE PFE opened at $27.99 on Friday. The firm has a market capitalization of $158.61 billion, a P/E ratio of -466.42, a P/E/G ratio of 1.09 and a beta of 0.70. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The stock’s 50-day simple moving average is $27.90 and its two-hundred day simple moving average is $27.69. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $37.80.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company’s revenue was down 19.5% on a year-over-year basis. During the same period in the prior year, the company earned $1.23 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 6.00%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Analysts Set New Price Targets

A number of brokerages have recently commented on PFE. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday. Morgan Stanley increased their price objective on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Finally, BMO Capital Markets reissued an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Ten analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.